NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis $1.78 +0.02 (+1.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.75▼$1.8250-Day Range$1.65▼$2.5252-Week Range$1.08▼$3.79Volume1.51 million shsAverage Volume1.74 million shsMarket Capitalization$116.54 millionP/E RatioN/ADividend YieldN/APrice Target$11.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Regulus Therapeutics alerts: Email Address Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside560.1% Upside$11.75 Price TargetShort InterestHealthy8.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.59) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector595th out of 936 stocksPharmaceutical Preparations Industry273rd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Regulus Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.20% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 18.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 3.3 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RGLS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows3 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.35% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regulus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regulus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of "Moderate Buy" by AnalystsJuly 16, 2024 | americanbankingnews.comRegulus Therapeutics' (RGLS) "Buy" Rating Reiterated at HC WainwrightJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 9, 2024 | prnewswire.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesJune 24, 2024 | prnewswire.comRegulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 4, 2024 | prnewswire.comRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesMay 16, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 16, 2024 | prnewswire.comRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 13, 2024 | theguardian.comStarwatch: the moon celebrates with a cruise past RegulusMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | prnewswire.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429May 6, 2024 | prnewswire.comRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 30, 2024 | prnewswire.comRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesApril 10, 2024 | seekingalpha.comRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDSee More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$11.75 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+562.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.69% Return on Assets-55.45% Debt Debt-to-Equity RatioN/A Current Ratio17.85 Quick Ratio17.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.69Miscellaneous Outstanding Shares65,470,000Free Float62,618,000Market Cap$116.21 million OptionableOptionable Beta1.62 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 55)CEO & Director Comp: $958.23kMs. Crispina Calsada CPA (Age 54)Chief Financial Officer Comp: $579.3kMr. Christopher Ray Aker J.D. (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $575.94kDr. Preston S. Klassen M.D. (Age 55)M.H.S., President, Head of Research & Development and Director Mr. Daniel J. Penksa (Age 38)VP of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMr. Edmund Lee Ph.D.Vice President of Translational MedicineMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMVanda PharmaceuticalsNASDAQ:VNDAXOMANASDAQ:XOMACodexisNASDAQ:CDXSRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 197,193 shares on 7/26/2024Ownership: 0.301%Opaleye Management Inc.Bought 170,308 shares on 5/29/2024Ownership: 0.260%RA Capital Management L.P.Bought 6,250,000 shares on 5/17/2024Ownership: 9.547%NEA Management Company LLCBought 6,467,802 shares on 5/15/2024Ownership: 9.879%Vanguard Group Inc.Bought 453,784 shares on 5/10/2024Ownership: 1.131%View All Insider TransactionsView All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions How have RGLS shares performed this year? Regulus Therapeutics' stock was trading at $1.28 on January 1st, 2024. Since then, RGLS stock has increased by 39.1% and is now trading at $1.78. View the best growth stocks for 2024 here. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.14. When did Regulus Therapeutics' stock split? Regulus Therapeutics's stock reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.30%). Insiders that own company stock include Joseph P Hagan, Crispina Calsada and Denis Drygin. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE) and Exelixis (EXEL). This page (NASDAQ:RGLS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts